Agenda
Tuesday, October 15, 2024
| 8:15 -- 8:25 AM | Welcome & Logistics Toby Hecht, Ph.D., and Naveena Janakiram, Ph.D., (TRP, DCTD, NCI) |
| 8:25 -- 8:35 AM | Report on current status of Gyn Cancers SPORE portfolio Naveena Janakiram, Ph.D. |
| Session 1: Overview of SPOREs Chair -- Naveena Janakiram, Ph.D., TRP, DCTD, NCI |
|
| 8:40 -- 8:50 AM | Scott H. Kaufmann, M.D. -- Mayo Clinic |
| 8:50 -- 9:00 AM | Anil K. Sood, M.D. -- MD Anderson cancer Center |
| 9:00 -- 9:10 AM | Ursula A. Matulonis, M.D. -- Dana-Farber Cancer Institute |
| 9:10 -- 9:20 AM | Kirsten Moysich Ph.D.-- Roswell Park Comprehensive Cancer center |
| 9:20 -- 9:30 AM | Ronald J. Buckanovich, M.D., Ph.D.-- University of Pittsburgh |
| 9:30 -- 9:40 AM | Ie-Ming Shih, M.D., Ph.D. -- Johns Hopkins University |
| 9:40 -- 9:50 AM | Tzyy-Choou Wu, M.D., Ph.D., M.P.H. -- Johns Hopkins University |
| 9:50 -- 10:00 AM | David Mutch, M.D. -- Washington University |
| 10:00 -- 10:10 AM | Break |
| 10:20 -- 11:00 PM | Special Talk: Stephanie Wethington, M.D., FDA Development and Regulation of Oncology Products: OOD and OCE Patient-centric Approaches |
| Session 2: Combination therapies and Immunotherapy Co-Chairs - Adekunle Odunsi, M.D, Ph.D., and Dr. Kaufmann, M.D. |
|
| 11:00 -- 11:20 AM | Matthew S. Block, M.D., Ph.D., Mayo Clinic A pulsed dendritic cell vaccine to prevent HGSOC recurrence |
| 11:20 -- 11:40 AM | Richard B. S. Roden, Ph.D., Johns Hopkins University Vaccination of cervical cancer patients with HPV16 L2E7E6 fusion protein aggregate to control minimal residual disease |
| 11:40 -- 12:00 AM | Panos A. Konstantinopoulos, M.D., Ph.D., Dana Farber Harvard Cancer Center DNA damage response (DDR) inhibitors and immunotherapy |
| 12:00 -- 12:20 AM | Kimberly Lynn Levinson, M.D., M.P.H., Johns Hopkins University Therapeutic Vaccination with pNGL4aCRTE6E7L2 for the Elimination of HPV16+ Cervical Dysplasia. |
| 12:20 -- 1:30 PM | Lunch |
| Session 3: DNA repair and PARP inhibition Co-Chairs -- Rugang Zhang Ph.D., and Kim Leslie, M.D. |
|
| 1:30 -- 1:50 PM | Scott H. Kaufmann, M.D., Ph.D., Mayo Clinic A novel mechanism of PARPi resistance |
| 1:50 -- 2:10 PM | Haider S. Mahdi, M.D., University of Pittsburg Use of Bet inhibitors to overcome resistance to PARPi |
| 2:10 -- 2:30 PM | Geoffrey Shapiro, M.D., Ph.D., Dana-Farber Cancer Institute PTEN deficiency as a determinant of sensitivity to combined ATR and PARP inhibition in high-grade serous ovarian cancer |
| 2:30 -- 2:50 PM | Kimberly Leslie, M.D., University of New Mexico p53: The Guardian of the Genome Morphs into the Guardian of the Cancer Cell |
| 2:50 -- 3:10 PM | Fiona Simpkins, M.D., University of Pennsylvania School of Medicine Parp inhibitor combinations in ovarian cancer..when and for whom? |
| 3:10 -- 3:20 PM | Break |
| 3:20 -- 4:10 PM | Working Group 1 Chair -- Ronald J. Buckanovich, M.D., Ph.D. Novel technologies for translating bench to bedside and beyond. |
| Session 4: Early-stage investigators Chair: Ronald J. Buckanovich, M.D., Ph.D. |
|
| 4:10 -- 4:20 PM | Hind Rafei, M.D., The University of Texas MD Anderson Cancer Center Epigenetic Reprogramming of CAR-NK cells to Enhance their Efficacy in the Acidic Tumor Microenvironment of Ovarian Cancer |
| 4:20 -- 4:30 PM | Heather Whitney, Ph.D., University of Chicago Artificial intelligence for pre-operative assessment of adnexal lesions from ultrasound images |
| 4:30 -- 4:40 PM | Rafet Basar, M.D., The University of Texas MD Anderson Cancer Center TROP2 Targeting Cord Blood-Derived CAR-NK Cells In Combination with PARP Inhibitor for the Management of Platinum Resistant Ovarian Cancer |
| 4:40 -- 4:50 PM | Teressa Boitano, M.D., The University of Alabama at Birmingham Provider Perspectives on the Transition to Primary HPV Testing for Cervical Cancer Screening |
| 4:50 -- 5:00 PM |
Sara Corvigno, M.D., Ph.D., M.D., The University of Texas MD Anderson Cancer Center |
| 5:00 -- 5:10 PM |
Q & A |
| 5:10 PM | Concluding remarks Naveena B. Janakiram, Ph.D., TRP, DCTD, NCI |
Wednesday, October 16, 2024
| Session 5: Tumor biology, early detection, and prevention Co-Chairs -- Bakum Gamez, M.D. and Doris M. Benbrook, Ph.D. |
|
| 8:15 -- 8:35 AM | Ie-Ming Shih, M.D., Ph.D. Detection and Prevention of Ovarian Cancer through Understanding its Precursor Lesions |
| 8:35 -- 8:55 AM | Robert C. Bast, M.D., MD Anderson Cancer center 21-year update on the NROSS screening trial |
| 8:55 -- 9:15 AM | Lan G. Coffman, M.D., Ph.D., University of Pittsburgh The role of fallopian tube stroma as a driver of ovarian cancer |
| 9:15 -- 9:25 AM | Vishal Chandra, Ph.D., University of Oklahoma Health Sciences Center Utilizing GLP-1R Agonist for Endometrial Cancer Therapy |
| 9:25 -- 9:35 AM | Rikki Cannioto, Ph.D., Roswell Park Comprehensive Cancer Center Leveraging Novel Body Composition Indices and Immuno-Metabolomic Biomarkers to Disentangle the Obesity Paradox in Epithelial Ovarian Cancer |
| 9:35 -- 9:45 AM | Break |
| 9:45 -- 10:35 PM | Working Group 2 Chair -- Anil K. Sood, M.D., MD Anderson Cancer Center Challenges in clinical research, patient approaches, availability of resources, and opportunities for collaborations, and future directions. |
| 10:35 -- 10:45 AM | Break |
| Session 6: Translating Innovation to Clinical trials Co-Chairs -- Anil K. Sood, M.D., and Ursula A. Matulonis, M.D. |
|
| 10:45 -- 11:05 AM | Ms. Stephanie Doebler (Patient advocate), Mayo Clinic, Minnesota Ovarian Cancer Alliance (MOCA) Patient Advocate Impact and Perspectives on Ovarian Cancer Research |
| 11:05 -- 11:25 AM | Andrew Sussman, Ph.D., University of New Mexico Health Equity in Endometrial Cancer |
| 11:25 -- 11:45 PM | Timothy Yap, M.B.B.S, Ph.D., F.R.C.P., MD Anderson Cancer center Drug discovery and clinical translation |
| 11:45 -- 12:05 PM | Adekunle Odunsi, M.D., Ph.D., University of Chicago Bench to bedside translation of an armed oncolytic vaccinia virus expressing a CXCR4 antagonist in ovarian cancer |
| 12:05 -- 12:25 PM | Pawel Kalinski, M.D., Ph.D., Roswell Park Comprehensive Cancer Center Dendritic Cell Therapies of Ovarian Cancer |
| 12:25 -- 12:35 PM |
Kimberley Levinson, M.D., Johns Hopkins University |
| 12:35 -- 12:45 PM |
Meeting Summary and Future Directions |
| 12:45 -- 12:55 PM | Concluding remarks and Adjourn. Naveena Janakiram, Ph.D., TRP, DCTD, NCI |